Phase 2 Hypertension Trial, Recruiting (NCT04715022)

Phase 2 Hypertension Trial, Recruiting NCT04715022 Sponsor: University of Kansas Medical Center Condition: Hypertension

Printed from Voxsanity (voxsanity.com.au) — NCT04715022 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hypertension

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Here is the eligibility information for this trial in plain English:

Who might be able to join this trial:

You have a Body Mass Index (BMI) over 30, which is classified as obese
You are between 35 and 65 years old
You are willing and able to stop taking any Vitamin C, Vitamin E, or omega-3/fish oil supplements at least 2 weeks before the trial begins
You are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

You have diabetes, based on specific blood sugar test results (confirm with trial site)
You are currently taking a statin (cholesterol-lowering medication) or blood pressure medication
You have high levels of fats called triglycerides in your blood, based on a fasting blood test (confirm with trial site)
You have high blood pressure readings of 130/80 or above (confirm with trial site)
You have a history of heart disease, such as a heart attack or having had a stent fitted
You have a history of vascular (blood vessel) disease, such as a bypass surgery or stroke

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 2 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04715022

Sponsor: University of Kansas Medical Center

Phase: Phase 2

Status: Recruiting

Condition: Hypertension

More information: https://clinicaltrials.gov/study/NCT04715022

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Here is the eligibility information for this trial in plain English:

Who might be able to join this trial:

You have a Body Mass Index (BMI) over 30, which is classified as obese
You are between 35 and 65 years old
You are willing and able to stop taking any Vitamin C, Vitamin E, or omega-3/fish oil supplements at least 2 weeks before the trial begins
You are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

You have diabetes, based on specific blood sugar test results (confirm with trial site)
You are currently taking a statin (cholesterol-lowering medication) or blood pressure medication
You have high levels of fats called triglycerides in your blood, based on a fasting blood test (confirm with trial site)
You have high blood pressure readings of 130/80 or above (confirm with trial site)
You have a history of heart disease, such as a heart attack or having had a stent fitted
You have a history of vascular (blood vessel) disease, such as a bypass surgery or stroke

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 2 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

University of Kansas Medical Center

Registry

ClinicalTrials.gov

Start date

17 June 2021

Est. completion

1 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Efficacy of infusion of ascorbic acid; Efficacy of infusion of ascorbic acid; Efficacy of infusion of ascorbic acid; Efficacy of infusion of ascorbic acid

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov